Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Conditions
Interventions
talaporfin sodium
Saline
+2 more
Locations
41
United States
Anniston, Alabama, United States
Huntsville, Alabama, United States
Anchorage, Alaska, United States
Laguna Hills, California, United States
Los Angeles, California, United States
Murrieta, California, United States
Start Date
November 1, 2014
Primary Completion Date
March 29, 2017
Completion Date
March 29, 2017
Last Updated
August 8, 2018
NCT07016620
NCT06312722
NCT06817733
NCT06265519
NCT04627701
NCT06225479
Lead Sponsor
Light Sciences Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions